Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial

多拉韦林/伊斯拉曲韦（100/0.75 毫克）每日一次与比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺作为 HIV-1 初始治疗的比较：一项 3 期随机、对照、双盲、非劣效性试验的 48 周结果

阅读：2
作者：Rockstroh,Jürgen K,Paredes,Roger,Cahn,Pedro,Molina,Jean-Michel,Sokhela,Simiso M,Hinestrosa,Federico,Kassim,Sheetal,Cunningham,Douglas,Ghosn,Jade,Bogner,Johannes R,Gatanaga,Hiroyuki,Asante-Appiah,Ernest,Zhang,Ying,Nwoke,Uchechukwu,Klopfer,Stephanie O,Eves,Karen,Squires,Kathleen,Correll,Todd,Fox,Michelle C,Pisculli,Mary L
期刊：Clinical Infectious Diseases影响因子：
时间：2025起止号：2025 Sep 16;81(2)：322-332
doi：10.1093/cid/ciaf077

Abstract

BACKGROUND: Doravirine/islatravir is an investigational regimen that is being studied for human immunodeficiency virus type 1 (HIV-1) treatment. METHODS: In this phase 3, double-blind, double-dummy trial (ClinicalTrials.gov NCT04233879), previously untreated adults with HIV-1 were randomized (1:1) and stratified by HIV-1 RNA (≤/>100 000 copies/mL) and CD4 count (

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。